Results from the EXPEDITE study of Remodulin® induction prior to Orenitram® therapy to be presented at ATS
Baseline patient data from the TETON studies of Tyvaso® Inhalation Solution in. | April 18, 2023
/PRNewswire/ United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today.